Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Talis Biomedical Corporation - common stock (NQ:TLIS)

4.380 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Talis Biomedical Corporation - common stock

< Previous 1 2 3 Next >
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Talis, TaskUs, and RTR on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific 
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
From Talis Biomedical Corporation
Via GlobeNewswire
New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Announces 1-for-15 Reverse Stock Split
From Talis Biomedical Corporation
Via GlobeNewswire
TALIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Talis Biomedical Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent Director
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Announces Business Update and First Quarter 2023 Financial Results
Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific 
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Corporation (TLIS) Stockholders: Robbins LLP is Investigating TLIS on Behalf of Shareholders
From Robbins LLP
Via Business Wire
Talis Announces Fourth Quarter and Full Year 2022 Financial Results
From Talis Biomedical Corporation
Via GlobeNewswire
Talis Biomedical Reports Third Quarter 2022 Financial Results
From Talis Biomedical Corporation
Via GlobeNewswire
NASDAQ:TLIS Long Term Investor Alert: Investigation of Potential Wrongdoing at Talis Biomedical Corporation
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- Certain directors of Talis Biomedical Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Final Deadline Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - March 08, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation... 
Via NewMediaWire
Topics Lawsuit
TLIS FINAL DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Talis Biomedical Corporation Investors with Losses to Secure Counsel Before Important March 8 Deadline in Securities Class Action TLIS
WHY: NEW YORK, NY - (NewMediaWire) - March 8, 2022 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Talis Biomedical Corporation (NASDAQ: TLIS) pursuant... 
Via NewMediaWire
Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - March 07, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation... 
Via NewMediaWire
Topics Lawsuit
Talis Biomedical Corporation (NASDAQ:TLIS) Investor Notice: Deadline in Lawsuit on March 8, 2021
San Diego, CA -- (SBWIRE) -- 03/07/2022 -- The Shareholders Foundation announced that a deadline is coming up on March 8, 2021 in the lawsuit filed for certain investors of Talis Biomedical Corporation... 
Via SBWire
Deadline Tuesday Notice: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
TLIS FINAL DEADLINE TUESDAY: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Talis Biomedical Corporation Investors with Losses to Secure Counsel Before Important March 8 Deadline in Securities Class Action - TLIS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Deadline Tuesday Alert: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Tuesday Deadline Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - March 02, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Talis Biomedical Corporation... 
Via NewMediaWire
Topics Lawsuit
7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Talis Biomedical Corporation with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
TLIS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Talis Biomedical Corporation Investors with Losses Over $100K to Secure Counsel Before Important March 8 Deadline in Securities Class Action TLIS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Talis Biomedical Corporation Investors with Losses Over $100K to Secure Counsel Before Important March 8 Deadline in Securities Class Action TLIS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A TOP RANKED LAW FIRM, Encourages Talis Biomedical Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action TLIS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.